HSR22-153: Real-World Time to Discontinuation of First-Line Venetoclax + Obinutuzumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
威尼斯人
奥比努图库单抗
医学
慢性淋巴细胞白血病
中止
伊布替尼
肿瘤科
淋巴瘤
内科学
白血病
作者
Xiaoxiao Lu,Qing Huang,Linda Wu,Bruno Émond,Shaun P. Forbes,Annalise Hilts,Stephanie Liu,Marie‐Hélène Lafeuille,Patrick Lefèbvre,Kerry A. Rogers
"HSR22-153: Real-World Time to Discontinuation of First-Line Venetoclax + Obinutuzumab in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma" published on 31 Mar 2022 by National Comprehensive Cancer Network.
PDF的下载单位、IP信息已删除
(2025-6-4)
Theprisoners
无极微光
DW
Nole
dde
Aurora
v0id
xing_xing
null
潇洒的惋清
秋风
cdercder
aajhajkahna
学术文献互助
aaaa
DOC_XIONG
云天河
arniu2008
初景
殷勤的紫槐
皖公网安备34019202002308
